Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravis.
Marcuse F, Hoeijmakers JGJ, Hochstenbag M, Hamid MA, Keijzers M, Mané-Damas M, Martinez-Martinez P, Verschuuren J, Kuks J, Beekman R, van der Kooi AJ, van Doorn P, van Es M, Maessen JJG, De Baets MHV. Marcuse F, et al. Among authors: verschuuren j. Neuromuscul Disord. 2023 May;33(5):417-424. doi: 10.1016/j.nmd.2023.03.005. Epub 2023 Mar 16. Neuromuscul Disord. 2023. PMID: 37037051 Free article.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: verschuuren j. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
International consensus guidance for management of myasthenia gravis: Executive summary.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. Sanders DB, et al. Among authors: verschuuren j. Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Neurology. 2016. PMID: 27358333 Free PMC article. Review.
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. Narayanaswami P, et al. Among authors: verschuuren j. Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. Neurology. 2021. PMID: 33144515 Free PMC article. Review.
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Lee I, Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJG, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Minisman G, Sonett JR, Wolfe GI; MGTX study group. Lee I, et al. Among authors: verschuuren jjg. Neurology. 2020 Aug 11;95(6):e755-e766. doi: 10.1212/WNL.0000000000010031. Epub 2020 Jul 1. Neurology. 2020. PMID: 32611638 Free PMC article. Clinical Trial.
Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK.
Lim JL, Augustinus R, Plomp JJ, Roya-Kouchaki K, Vergoossen DLE, Fillié-Grijpma Y, Struijk J, Thomas R, Salvatori D, Steyaert C, Blanchetot C, Vanhauwaert R, Silence K, van der Maarel SM, Verschuuren JJ, Huijbers MG. Lim JL, et al. Among authors: verschuuren jj. Sci Rep. 2023 May 8;13(1):7478. doi: 10.1038/s41598-023-32641-1. Sci Rep. 2023. PMID: 37156800 Free PMC article.
Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction.
Braun A, Shekhar S, Levey DF, Straub P, Kraft J, Panagiotaropoulou GM, Heilbron K, Awasthi S, Meleka Hanna R, Hoffmann S, Stein M, Lehnerer S, Mergenthaler P, Elnahas AG, Topaloudi A, Koromina M, Palviainen T, Asbjornsdottir B, Stefansson H, Skuladóttir AT, Jónsdóttir I, Stefansson K, Reis K, Esko T, Palotie A, Leypoldt F, Stein MB, Fontanillas P; Estonian Biobank Research Team; 23andMe Research Team; Kaprio J, Gelernter J, Davis LK, Paschou P, Tannemaat MR, Verschuuren JJGM, Kuhlenbäumer G, Gregersen PK, Huijbers MG, Stascheit F, Meisel A, Ripke S. Braun A, et al. Among authors: verschuuren jjgm. Nat Commun. 2024 Nov 13;15(1):9839. doi: 10.1038/s41467-024-53595-6. Nat Commun. 2024. PMID: 39537604 Free PMC article.
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.
Kummer LYL, Fernández Blanco L, Kreher C, Bos A, Kuijper LH, Verstegen NJM, van de Sandt CE, Konijn VAL, Duurland MC, Menage C, Jorritsma T, Steenhuis M, Hagen RR, van den Dijssel J, de Jongh R, Ashhurst T, van Gils MJ, Garcia-Vallejo JJ, Claireaux M, Stalman EW, van Dam KPJ, Wieske L, Boekel L, Wolbink G, Tas SW, Rispens T, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A; T2B! Immunity Against SARS-CoV-2 Study Group. Kummer LYL, et al. RMD Open. 2024 Oct 7;10(4):e004664. doi: 10.1136/rmdopen-2024-004664. RMD Open. 2024. PMID: 39375177 Free PMC article.
313 results